Skip to content
OpenCapital
Get started

Relmada Therapeutics, Inc. RLMD Accrued bonuses

Accrued bonuses at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
——

Other financials

Income statement

See full
Operating income-$19.5M-6.8%
Net income-$19.1M-8.5%
EPS (diluted)-$0.22+62.1%

Balance sheet

See full
Cash & equivalents$9.8M+750%
Total debt$104.1M-40.4%
Total equity$218.7M+875%
Total assets$235.4M+750%

Cash flow

See full
Operating cash flow-$15.1M+16.6%

Valuation

See full
Market cap$677.17M+2,907%

Returns & leverage

See full
Return on equity-48.8%-20.0pp
Debt / equity0.9×0.0×
Current ratio18.3×+13.0×

Where this comes from

Reported directly by Relmada Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccruedBonusesCurrent.

The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Relmada Therapeutics, Inc.'s accrued bonuses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Relmada Therapeutics, Inc.'s accrued bonuses?
Relmada Therapeutics, Inc. (RLMD) reported accrued bonuses of $516.3K in Q1 2026.
How has Relmada Therapeutics, Inc.'s accrued bonuses changed year-over-year?
Relmada Therapeutics, Inc.'s accrued bonuses increased by 12.9% year-over-year, from $457.3K to $516.3K.
What does accrued bonuses mean?
The estimated liability for performance-based compensation earned by employees that remains unpaid at the balance sheet date. This metric reflects the company's commitment to talent retention and the alignment of management incentives with corporate milestones. It is a key component of short-term personnel-related liabilities.